Mylan explores the patient-centric road to biosimilars

Register now at

Register now at

ISELIN, NEW JERSEY, USA, July 12, 2017 / — SMi Group has announced that Mr Chrys Kokino, Head Biologics Commercial at Mylan has joined the speaker line-up for the 4th annual Biosimilars North America conference in New Jersey.

Chrys will present a talk entitled "The Road to Biosimilars: Reaching our destination with the patient in mind". This session, focusing on biosimilar usability and effectivity, will look into strategies, obstacles and lessons learned from the global market and adapting these for future US launches.

Chrys joins a speaker line-up comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Harvest Moon Pharmaceuticals, Momenta, FUJIFILM Diosynth, Oncobiologics, Adelio, Covance, Zuckerman & Spaeder and more.

The full roster of speakers and their topics can be found on

This year, the conference will also explore significant developmental topics within the sector including the impact of FDA’s newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs.

Registration is now live on the event website. For more information visit:

4th Biosimilars North America
November 15 & 16, 2017
Renaissance Woodbridge Hotel, Iselin, NJ, USA

— END —
For delegate registration enquiries, contact Fateja Begum on For media enquiries, contact Honey de Gracia at

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Honey de Gracia
SMi Group Ltd
+44 (0)20 7827 6102
email us here

Source: EIN Presswire